About us
Our team
Our science
Radiopharmaceuticals
Our technology
Abstracts & publications
Our pipeline
News
All news
ASX releases
Media releases
Investors
Share price
Annual reports
Shareholder newsletter
Analyst coverage
Corporate governance
Corporate policies
Contact us
About us
Our team
Our science
Radiopharmaceuticals
Our technology
Abstracts & publications
Our pipeline
News
All news
ASX releases
Media releases
Investors
Share price
Shareholder newsletter
Analyst coverage
Corporate governance
Corporate policies
Contact us
News
ASX Releases
May 29, 2023
FDA Pre-IND Meeting Supports an IND Application for RAD101
Read more
Read more
May 9, 2023
RAD Receives FDA Orphan Drug Designation for Trivehexin (RAD301) in Pancreatic Cancer
Read more
Read more
April 17, 2023
RAD Enters into Supply Agreement with Terthera for Terbium-161 Isotope
Read more
Read more
March 28, 2023
RAD Invited to Participate in Jefferies Radiopharma Innovation Summit
Read more
Read more
March 28, 2023
RAD Receives $1.56M R&D Tax Incentive
Read more
Read more
March 27, 2023
RAD and GenesisCare Partner to Develop Novel Radiopharmaceuticals in Australia
Read more
Read more
Load More
MEDIA releases
May 2, 2023
Positive new publication for RAD301 platform
Read more
Read more
February 21, 2023
FNN Interview with CEO about RAD's ambition to list on Nasdaq
Read more
Read more
February 16, 2023
Investor Webinar
Read more
Read more
February 14, 2023
RAD CEO interview with Proactive Investors and announcement of Nasdaq listing initiation
Read more
Read more
December 1, 2022
GenesisCare and RAD Partner to Bring World First Novel Radiopharmaceuticals to Australian Cancer Patients
Read more
Read more
October 6, 2022
CEO Interview series with Wholesale Investor
Read more
Read more
Load more
Sign up to our mailing list.
Receive all the latest news from Radiopharm Theranostics.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form. Please fill out all starred fields.